Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22771702 | 0.97 | TSHR (0.48) | TSHRALDH1A1MEN1POLBKMT2A | |
| SCHEMBL14493087 | 0.89 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL18807806 | 0.87 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL4775369 | 0.85 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL25645226 | 0.85 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL12166057 | 0.85 | MEN1 (0.38) | TSHRALDH1A1MEN1POLBKMT2A | |
| SCHEMBL8386894 | 0.84 | TSHR (0.55) | TSHRALDH1A1MEN1POLBKMT2A | |
| SCHEMBL5699187 | 0.84 | TSHR (0.55) | TSHRALDH1A1MEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL22771935 | 0.82 | TSHR (0.52) | TSHRALDH1A1MEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL22771703 | 0.82 | TSHR (0.52) | TSHRALDH1A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234553-A2 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |